MOR 208

Drug Profile

MOR 208

Alternative Names: anti-CD19 MAb XmAb5574; anti-CD19 MoAb XmAb5574; MOR-00208; MOR-208; XENP-5574; XmAb-5574

Latest Information Update: 19 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xencor
  • Developer MorphoSys; The Ohio State University Comprehensive Cancer Center; Xencor
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diffuse large B cell lymphoma
  • Phase II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 15 Jun 2018 Preliminary safety and efficacy data from the phase II COSMOS trial in Chronic lymphocytic leukaemia released by MorphoSys
  • 02 May 2018 MorphoSys anticipates launch of MOR 208 for the treatment of Diffuse large B cell lymphoma in USA in 2020
  • 13 Mar 2018 Updated adverse events and efficacy data from the phase II L-MIND trial in Diffuse large B cell lymphoma released by MorphoSys
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top